GSK claims Amgen v Sanofi decision “threatens” innovation
29-04-2021
SCOTUS weighs future of assignor estoppel
11-01-2021
Willy Barton / Shutterstock.com
Patent law experts and pharmaceutical companies have lent their support to Merck Sharp & Dohme (MSD) in its effort to confirm the patent-eligibility of genus claims at the US Supreme Court.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
GSK, Amgen, professors, GlaxoSmithKline, Merck Sharp & Dohme, Federal Circuit, Idenix, genus claims, patent eligibility, Supreme Court
